Podcasts
Filter News
Found 15 articles
-
Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss BioSpace's tenth annual NextGen list of the hottest new life sciences companies.
-
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
12/21/2023
How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding. -
On this episode of the Weekly: Biden administration puts pressure on the biopharma industry; renewed interest in psychedelics after MindMed announces LSD-based candidate meets primary endpoint; bluebird changes its tune.
-
What VCs really think of the market right now with MPM Capital, Endeavor and Two Bear Capital
12/14/2023
What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen. -
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
12/13/2023
This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda's $100m purchase and AI regulatory developments in Europe. -
Fast and furious evolution: how to ensure AI is catalyst for positive societal change with Micros...
12/12/2023
In this episode we dive into regulation, real-time management, and AI's various applications and how it can streamline different processes with guests from Microsoft and IQVIA. -
In this episode, hear from senior leaders at Microsoft and IQVIA to get their take on how generative AI is impacting productivity, employee engagement and how to mitigate risks.
-
This week we discuss ups and downs in the weight loss and ADC markets - including Altimmune, Pfizer setbacks, AbbVie's ImmunoGen buy and more.
-
In this third episode of Denatured's series on AI in drug discovery, we discuss patient behavior and its influence on clinical trials and AI models with guests from GSK, IQVIA, Exelixis and DataHow.
-
Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction, with guests from GSK, IQVIA, Exelixis and DataHow.
-
Deals, Dupixent and GLP-1 drug shortages
11/29/2023
This week on The Weekly we talk struggles with GLP-1 drug shortages and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for Dupixent in COPD. Plus, Merck buys Caraway, Beigene's deal with Ensem, ups and downs for Flagship. -
CRISPR gene-editing has had its first ever approval in the UK. Will the FDA follow suit? What can patients expect the price tag to be?
-
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise.
-
Zepbound vs Wegovy: A Two-Horse Race
11/15/2023
In this episode BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss Zepbound, Wegovy, the weight loss race and the future of this drug class. -
This week, in (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's reported Q3 earnings. They also tackle what's going on at Pfizer, ADCs, deals and more.